Subtopic Deep Dive
Hemophilia Prophylaxis
Research Guide
What is Hemophilia Prophylaxis?
Hemophilia prophylaxis is the regular administration of factor VIII or IX concentrates to prevent spontaneous bleeding episodes and joint damage in patients with severe hemophilia A or B.
Prophylactic regimens aim to maintain factor levels above 1% to reduce hemorrhage frequency and arthropathy. Landmark trials like Manco-Johnson et al. (2007) demonstrated prophylaxis superiority over on-demand treatment in boys with severe hemophilia A (1906 citations). Over 50 papers since 2006 have refined dosing, adherence, and outcomes in this subtopic.
Why It Matters
Prophylaxis guidelines from studies like Manco-Johnson et al. (2007) reduced joint bleeds by 96% in children, enabling normal activity and lowering lifelong disability costs. Oldenburg (2015) highlighted optimized regimens cutting annualized bleed rates by 80-90% in adults. These advances shape WHO and ISTH standards, impacting 400,000 global patients by improving quality-adjusted life years.
Key Research Challenges
Dosing Optimization
Balancing factor VIII/IX trough levels against infusion frequency remains challenging due to inter-patient pharmacokinetic variability. Oldenburg (2015) notes current regimens often exceed optimal dosing, increasing costs by 2-3 fold. Adherence drops with frequent infusions, per ESPRIT Study (Gringeri et al., 2011).
Inhibitor Development
Up to 30% of prophylaxis patients develop inhibitors complicating treatment. FENOC Study (Astermark et al., 2006) compared bypassing agents but showed inconsistent hemostasis control (467 citations). Hay et al. (2011) randomized immune tolerance regimens with variable success rates.
Long-term Adherence
Patient adherence to lifelong prophylaxis declines over time due to pain and lifestyle burdens. Gringeri et al. (2011) ESPRIT trial reported 20-30% non-compliance in children transitioning to adults. Blanchette et al. (2014) standardized definitions to better track outcomes (715 citations).
Essential Papers
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
Marilyn J. Manco‐Johnson, Thomas C. Abshire, Amy D. Shapiro et al. · 2007 · New England Journal of Medicine · 1.9K citations
Prophylaxis with recombinant factor VIII can prevent joint damage and decrease the frequency of joint and other hemorrhages in young boys with severe hemophilia A. (ClinicalTrials.gov number, NCT00...
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
Lindsey A. George, Spencer K. Sullivan, Adam Giermasz et al. · 2017 · New England Journal of Medicine · 735 citations
We found sustained therapeutic expression of factor IX coagulant activity after gene transfer in 10 participants with hemophilia who received the same vector dose. Transgene-derived factor IX coagu...
Definitions in hemophilia: communication from the SSC of the ISTH
Victor S. Blanchette, Nigel S. Key, L.R. Ljung et al. · 2014 · Journal of Thrombosis and Haemostasis · 715 citations
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan, Liron Walsh, Will Lester et al. · 2017 · New England Journal of Medicine · 663 citations
The infusion of AAV5-hFVIII-SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stab...
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
Jan Astermark, Sharyne Donfield, Donna DiMichele et al. · 2006 · Blood · 467 citations
Abstract The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor-bypassing activity), an activated prothrombin complex concentr...
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
A. Gringeri, Björn Lundin, Sylvia von Mackensen et al. · 2011 · Journal of Thrombosis and Haemostasis · 447 citations
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A
John Pasi, Savita Rangarajan, Nina Mitchell et al. · 2020 · New England Journal of Medicine · 438 citations
Gene therapy with AAV5-hFVIII-SQ vector in participants with hemophilia A resulted in sustained, clinically relevant benefit, as measured by a substantial reduction in annualized rates of bleeding ...
Reading Guide
Foundational Papers
Start with Manco-Johnson et al. (2007, 1906 citations) for prophylaxis vs. episodic proof in children, then Blanchette et al. (2014, 715 citations) for standardized definitions.
Recent Advances
Study Pasi et al. (2020, 438 citations) for AAV5 gene therapy multiyear outcomes reducing prophylaxis need, and George et al. (2017, 735 citations) for factor IX variants.
Core Methods
Core techniques include randomized controlled trials (ESPRIT, Gringeri et al., 2011), PK/PD modeling (Oldenburg, 2015), and bypassing agent comparisons (FENOC, Astermark et al., 2006).
How PapersFlow Helps You Research Hemophilia Prophylaxis
Discover & Search
Research Agent uses searchPapers('hemophilia prophylaxis joint outcomes') to retrieve Manco-Johnson et al. (2007, 1906 citations), then citationGraph reveals 500+ citing works on dosing strategies. exaSearch uncovers recent adherence studies, while findSimilarPapers links to Gringeri et al. (2011) ESPRIT trial.
Analyze & Verify
Analysis Agent applies readPaperContent on Manco-Johnson et al. (2007) to extract bleed rate reductions, then verifyResponse with CoVe cross-checks claims against 10 similar trials. runPythonAnalysis imports pandas to meta-analyze annualized bleed rates from ESPRIT (Gringeri et al., 2011) and Oldenburg (2015), with GRADE grading assigning high evidence to prophylaxis efficacy.
Synthesize & Write
Synthesis Agent detects gaps in inhibitor prophylaxis via contradiction flagging between FENOC (Astermark et al., 2006) and Hay et al. (2011). Writing Agent uses latexEditText for regimen tables, latexSyncCitations for 20-paper bibliography, and latexCompile to generate review manuscripts. exportMermaid visualizes dosing PK/PD flows.
Use Cases
"Meta-analyze bleed rates from hemophilia prophylaxis trials using Python"
Research Agent → searchPapers('prophylaxis trials bleed rates') → Analysis Agent → runPythonAnalysis(pandas meta-analysis of Manco-Johnson 2007 + ESPRIT 2011 data) → outputs CSV of pooled RR=0.04 for joint bleeds with CI.
"Draft LaTeX review on factor VIII prophylaxis outcomes"
Synthesis Agent → gap detection (Oldenburg 2015) → Writing Agent → latexEditText(structured sections) → latexSyncCitations(15 papers) → latexCompile → researcher gets PDF manuscript with figures.
"Find code for hemophilia PK modeling from prophylaxis papers"
Research Agent → paperExtractUrls(Oldenburg 2015) → Code Discovery → paperFindGithubRepo → githubRepoInspect → outputs PK simulation Jupyter notebooks linked to 5 papers.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(100+ prophylaxis papers) → citationGraph → GRADE synthesis → structured report on dosing efficacy from Manco-Johnson et al. (2007). DeepScan applies 7-step CoVe to verify inhibitor claims in Astermark et al. (2006), outputting verified summaries. Theorizer generates hypotheses on extended half-life factors from George et al. (2017) gene therapy data.
Frequently Asked Questions
What is hemophilia prophylaxis?
Regular scheduled infusions of factor VIII/IX to maintain levels >1% and prevent bleeds, as defined by Blanchette et al. (2014).
What are key methods in prophylaxis research?
Randomized trials compare prophylaxis vs. on-demand (Manco-Johnson et al., 2007; Gringeri et al., 2011) and test PK-tailored dosing (Oldenburg, 2015).
What are the most cited papers?
Manco-Johnson et al. (2007, 1906 citations) proves prophylaxis prevents joint disease; Blanchette et al. (2014, 715 citations) standardizes terms.
What open problems exist?
Optimal dosing amid PK variability (Oldenburg, 2015), inhibitor bypassing consistency (Astermark et al., 2006), and adult adherence remain unresolved.
Research Hemophilia Treatment and Research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hemophilia Prophylaxis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Hemophilia Treatment and Research Research Guide